.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Express Scripts
AstraZeneca
Merck
Boehringer Ingelheim
QuintilesIMS
Daiichi Sankyo
Moodys
Teva
Dow

Generated: November 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019959

« Back to Dashboard
NDA 019959 describes NOVOLIN N, which is a drug marketed by Novo Nordisk Inc and is included in two NDAs. It is available from three suppliers. Additional details are available on the NOVOLIN N profile page.

The generic ingredient in NOVOLIN N is insulin susp isophane semisynthetic purified human. There are thirty-eight drug master file entries for this compound. Additional details are available on the insulin susp isophane semisynthetic purified human profile page.

Summary for 019959

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0

Suppliers and Packaging for NDA: 019959

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NOVOLIN N
insulin susp isophane recombinant human
INJECTABLE;INJECTION 019959 NDA Novo Nordisk 0169-1834 0169-1834-02 1 VIAL in 1 CARTON (0169-1834-02) > 10 mL in 1 VIAL
NOVOLIN N
insulin susp isophane recombinant human
INJECTABLE;INJECTION 019959 NDA Novo Nordisk 0169-1834 0169-1834-11 1 VIAL in 1 CARTON (0169-1834-11) > 10 mL in 1 VIAL

Summary for product number 001

Active Rx/OTC/Discontinued:OTCDosage:INJECTABLE;INJECTIONStrength100 UNITS/ML
Approval Date:Jul 1, 1991TE:RLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Citi
QuintilesIMS
Farmers Insurance
Cipla
Dow
Chinese Patent Office
US Department of Justice
Accenture
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot